Genenta Science S.p.A. (GNTA) is a leading biopharmaceutical company, headquartered in Milan, Italy. It was founded in 2014 by a group of eminent scientists including Luigi Naldini, Bernhard Gentner, and Maria Grazia Roncarolo with a mission to revolutionize the treatment of cancer through gene and cell therapy.
At its core, Genenta seeks to convert an individual's own blood cells into potent therapeutic weapons capable of attacking cancer cells. The company's approach leverages hematopoietic stem/progenitor cells (HSPCs) as a vehicle to deliver tumor-selected therapeutic proteins. It involves ex vivo gene transfer into autologous HSPCs to allow the production and release of anti-cancer proteins directly at the tumour site. This is synchronized with the generation of an armed and self-renewable effector cell compartment that has the potential to deliver potent and durable therapeutic benefit, thereby overcoming the limitations of other forms of gene and cell therapy which lack tumour specificity and have limited persistence.
Genenta has a robust pipeline that encompasses a broad range of hematological and solid cancer indications. Its most advanced candidate, Temferon™ is currently in Phase I/II clinical trial for multiple myeloma, glioblastoma multiforme, and acute myeloid leukemia. Each project in Genenta’s pipeline has stemmed from extensive research and development powered by a highly specialized in-house scientific team and collaborations with leading research institutions.
Critical to Genenta's success is the strength of its leadership, with a team of seasoned industry professionals and scientists who bring a depth of experience and expertise to the company. The company also boasts an illustrious scientific advisory board comprising some of the world's most recognized leaders in gene therapy and its clinical application.
In 2020, Genenta secured €13.2 million ($14.7 million) in Series B funding, reflecting the faith of investors in the company’s promising approach to cancer treatment. The funding round was led by Italian venture capital firm Sofinnova Partners.
With strategic partnerships, a strong financial footing, continuous innovation, and a team of committed professionals, Genenta Science is well-positioned to achieve its ultimate goal of creating a new paradigm in cancer immunotherapies and improving patient outcomes around the world. Genenta has made significant strides in the rapidly evolving field of gene therapy, and its work could be transformative in redefining cancer treatment.